The IL-33 monoclonal antibody developed by Sanofi (SNY.US) and Regeneron (REGN.US) has been clinically approved again in China for the treatment of chronic sinusitis.

The class 1 new drug itepekimab injection, submitted by Sanofi (SNY.US), has been approved for clinical use and is intended for the treatment of patients with chronic rhinosinusitis without nasal polyps (CRSsNP).

Zhitong FinanceJan 15 21:18

Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186

Futu NewsJan 15 19:31 · Ratings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Yahoo FinanceJan 15 19:00

Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value

CNBCJan 15 07:54

Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.

BenzingaJan 15 03:39

Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?

Simply Wall StJan 15 00:36